Accipiter Biosciences has filed a notice of an exempt offering of securities to raise $10,492,778.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Accipiter Biosciences is raising up to $10,492,778.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Accipiter Biosciences
Accipiter Biosciences is a biotechnology company that designs and develops de novo protein therapies to address some of the worlds most complex diseases. Its primary focus is on creating single-agent biologics that are custom-engineered to engage multiple biological pathways at once, overcoming the limitations of traditional combination therapies. The company uses advanced computational protein design to build novel, multifunctional therapeutics that would not be possible with conventional drug modalities, aiming to provide more precise and effective treatment options. By being unbound by natural limitations, Accipiter Biosciences positions itself at the forefront of next-generation biologics, seeking to redefine how complex diseases are treated through innovative protein engineering. The firm emphasizes a new therapeutic approach in which precision and multifunctionality coexist within a single molecule, reflecting its ambition to transform patient care through cutting-edge science and technology.
To learn more, visit https://www.accipiterbio.com/
LinkedIn: https://www.linkedin.com/company/accipiter-biosciences
Contact:
Matthew Bick, Chief Executive Officer
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.